Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Rex Horton"'
Autor:
Fillos, John, Sparr, Anton E.
Publikováno v:
Journal (Water Pollution Control Federation), 1981 May 01. 53(5), 241a-243a.
Externí odkaz:
https://www.jstor.org/stable/25041131
Autor:
William L Redmond, Yoshinobu Koguchi, Annah S Rolig, Noriko Iwamoto, Takashi Shimada, Elizabeth R Sturgill, Zhaoyu Sun, Venkatesh Rajamanickam, Brady Bernard, Peter G Traber, Eliezer Zomer, J Rex Horton, Harold Shlevin
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 4 (2021)
Background PD-1/PD-L1 engagement and overexpression of galectin-3 (Gal-3) are critical mechanisms of tumor-induced immune suppression that contribute to immunotherapy resistance. We hypothesized that Gal-3 blockade with belapectin (GR-MD-02) plus ant
Externí odkaz:
https://doaj.org/article/b74b3ece4a084cb7ac2ccf373351e2ec
Autor:
Yaping Wu, Brendan D. Curti, Zhaoyu Sun, William L. Redmond, Brady Bernard, Christopher B. Fountain, Peter G. Traber, Takashi Shimada, Yoshinobu Koguchi, Rom Leidner, Eliezer Zomer, Elizabeth Sturgill, George Morris, Venkatesh Rajamanickam, Noriko Iwamoto, Annah S Rolig, Ian Hilgart-Martiszus, J. Rex Horton, Shu Ching Chang, Harold Shlevin
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 4 (2021)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundPD-1/PD-L1 engagement and overexpression of galectin-3 (Gal-3) are critical mechanisms of tumor-induced immune suppression that contribute to immunotherapy resistance. We hypothesized that Gal-3 blockade with belapectin (GR-MD-02) plus anti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a1c844347afeb00988b18adab8210ae
https://jitc.bmj.com/content/9/4/e002371.full
https://jitc.bmj.com/content/9/4/e002371.full
Publikováno v:
EquityBites (M2). 01/16/2013.
Autor:
Naga Chalasani, Manal F. Abdelmalek, Guadalupe Garcia-Tsao, Raj Vuppalanchi, Naim Alkhouri, Mary Rinella, Mazen Noureddin, Maxmillan Pyko, Mitchell Shiffman, Arun Sanyal, Adam Allgood, Harold Shlevin, Rex Horton, Eliezer Zomer, William Irish, Zachary Goodman, Stephen A. Harrison, Peter G. Traber, Manal Abdelmalek, Luis Balart, Brian Borg, Michael Charlton, Hari Conjeevaram, Michael Fuchs, Reem Ghalib, Pierre Gholam, Dina Halegoua-De Marzio, Stephen Harrison, Christopher Jue, Nyingi Kemmer, Kris Kowdley, Michelle Lai, Eric Lawitz, Rohit Loomba, Angelo Paredes, Don Rockey, Miguel Rodriguez, Raymond Rubin, Michael Ryan, Andrew Scanga, Thomas Sepe, Brent Tetri, Paul Thuluvath, Dawn Torres, John Vierling, Julia Wattacheril, Amanda Weiland, Donald Zogg
Publikováno v:
Gastroenterology. 158(5)
Background & Aims Increased levels of galectin 3 have been associated with nonalcoholic steatohepatitis (NASH) and contribute to toxin-induced liver fibrosis in mice. GR-MD-02 (belapectin) is an inhibitor of galectin 3 that reduces liver fibrosis and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8ceabcdee7e0914cf6f4b79f06e59fe
https://pubmed.ncbi.nlm.nih.gov/31812510
https://pubmed.ncbi.nlm.nih.gov/31812510
Autor:
Abdelmalek, Manal, Balart, Luis, Borg, Brian, Chalasani, Naga, Charlton, Michael, Conjeevaram, Hari, Fuchs, Michael, Ghalib, Reem, Gholam, Pierre, Halegoua-De Marzio, Dina, Harrison, Stephen, Jue, Christopher, Kemmer, Nyingi, Kowdley, Kris, Lai, Michelle, Lawitz, Eric, Loomba, Rohit, Noureddin, Mazen, Paredes, Angelo, Rinella, Mary, Rockey, Don, Rodriguez, Miguel, Rubin, Raymond, Ryan, Michael, Sanyal, Arun, Scanga, Andrew, Sepe, Thomas, Shiffman, Mitchell, Tetri, Brent, Thuluvath, Paul, Torres, Dawn, Vierling, John, Wattacheril, Julia, Weiland, Amanda, Zogg, Donald, Abdelmalek, Manal F. 2, Garcia-Tsao, Guadalupe 3, Vuppalanchi, Raj 1, Alkhouri, Naim 4, Pyko, Maxmillan 1, Allgood, Adam 9, Shlevin, Harold 9, Horton, Rex 9, Zomer, Eliezer 9, Irish, William 10, Goodman, Zachary 11, Harrison, Stephen A. 12, Traber, Peter G. 9
Publikováno v:
In Gastroenterology April 2020 158(5):1334-1345
Publikováno v:
Galectin Therapeutics Inc. MarketLine Company Profile. 4/1/2021, p1-19. 19p.
Publikováno v:
Galectin Therapeutics Inc. MarketLine Company Profile. 2/21/2020, p1-19. 19p.
Publikováno v:
Circus Fanfare; Aug2024, Vol. 54 Issue 3, p20-20, 2/3p